Ardelyx Completes Enrollment Ahead of Schedule in Phase 3 IBSRELA Trial for Chronic Idiopathic Constipation

Bitget2026/11/03 13:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ardelyx completed enrollment ahead of schedule in its Phase 3 ACCEL trial of IBSRELA (tenapanor) for adults with chronic idiopathic constipation.
Topline results are expected in the second half of 2027, assessing the drug’s safety and sustained relief of constipation.
IBSRELA is currently approved in the United States for adults with irritable bowel syndrome with constipation, but not chronic idiopathic constipation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardelyx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030800PRIMZONEFULLFEED9869003) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ardelyx Completes Enrollment Ahead of Schedule in Phase 3 IBSRELA Trial for Chronic Idiopathic Constipation

You may also like

Crypto prices